AKT1 and breast cancer: A previous report suggested that transient inhibition of Akt phosphorylation in trastuzumab-treated HER2+ breast cancer cells can lead to increased expression of ADAM17 and consequently increased expression of the lower-molecular-weight (40 kDa) soluble form of HRG [49].